Beyond cholesterol lowering: Pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome

Current Vascular Pharmacology

Volumn 6, Issue 4, 2008, Pages 271-281

  Yamaoka Tojo, Minako ^a   Tojo, Taiki ^a   Izumi, Tohru ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anion exchange resins; Bile acids; Diabetes mellitus; Inflammation; Insulin resistance; Metabolic syndrome; Obesity; Pleiotropic effects

Indexed keywords

ACARBOSE; BILE ACID SEQUESTRANT; BOFU TSUSHO SAN; CHENODEOXYCHOLIC ACID; CHINESE DRUG; COLESEVELAM; COLESTILAN; COLESTIPOL; COLESTYRAMINE; DIGOXIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FUROSEMIDE; GEMFIBROZIL; GLIBENCLAMIDE; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PENICILLIN G; PLACEBO; PROPRANOLOL; QUINIDINE; SULFONYLUREA DERIVATIVE; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; WARFARIN; ANION EXCHANGE RESIN; ANTILIPEMIC AGENT; BILE ACID; CHOLESTEROL;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; ENERGY METABOLISM; ENTEROHEPATIC CIRCULATION; FLATULENCE; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PLEIOTROPY; PRIMARY PREVENTION; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT; BLOOD; CARDIOVASCULAR DISEASE; DOWN REGULATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HISTORY; INFLAMMATION; LIPID METABOLISM; METABOLISM; TREATMENT OUTCOME;

ANION EXCHANGE RESINS; ANTILIPEMIC AGENTS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL; DOWN-REGULATION; ENERGY METABOLISM; ENTEROHEPATIC CIRCULATION; HISTORY, 20TH CENTURY; HUMANS; INFLAMMATION; LIPID METABOLISM; METABOLIC SYNDROME X; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 55449128648     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016108785909698     Document Type: Review

References (140)

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
3. Anderson JW, Brinkman-Kaplan VL, Lee H, Wood CL. Relationship of weight loss to cardiovascular risk factors in morbidly obese individuals. J Am Coll Nutr 1994; 13: 256-61.
4. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110: 2952-67.
5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
6. Matsuzawa Y. Metabolic syndrome - definition and diagnostic criteria in Japan. J Atheroscler Thromb 2005; 12: 301.
7. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745-9.
8. Heng D, Ma S, Lee JJ, Tai BC, Mak KH, Hughes K, et al. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 2006; 186: 367-73.
9. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-9.
10. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-90.
11. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 42-6.
12. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005; 36: 1366-71.
13. Insull W, Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99: 257-73.
14. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74.
15. Yamakawa T, Takano T, Utsunomiya H, Kadonosono K, Okamura A. Effect of Colestimide Therapy for Glycemic Control in Type 2 Diabetes Mellitus with Hypercholesterolemia. Endocr J 2007; 54: 53-8.
16. Bays HE, Goldberg RB. The 'forgotten' bile Acid sequestrants: is now a good time to remember? Am J Ther 2007; 14: 567-80.
17. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69: 313-24.
18. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40.
19. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990; 264: 3013-7.
20. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
21. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007-12.
22. Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-9.
23. Insull W, Jr., Toth P, Mullican W, Hunninghake D, Burke S, Donovan JM, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001; 76: 971-82.
24. Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159: 1893-900.
25. Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001; 24: 467-74.
26. Hunninghake D, Insull W, Jr., Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001; 158: 407-16.
27. McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005; 21: 1403-12.
28. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110: 352-60.
29. Kobayashi M, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, Noso S, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007; 56: 239-47.
30. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-9.
31. Dawson P. Bile secretion and the enterohepatic circulation of bile acids. Gastrointest Liver Dis 2002; 1051-64.
32. Stapleton G, Steel M, Richardson M, Mason JO, Rose KA, Morris RG, et al. A novel cytochrome P450 expressed primarily in brain. J Biol Chem 1995; 270: 29739-45.
33. Packard CJ, Shepherd J. The hepatobiliary axis and lipoprotein metabolism: effects of bile acid sequestrants and ileal bypass surgery. J Lipid Res 1982; 23: 1081-98.
34. Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002; 23: 443-63.
35. Einarsson K, Ericsson S, Ewerth S, Reihner E, Rudling M, Stahlberg D, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991; 40 Suppl 1: S53-8.
36. Bennion LJ, Grundy SM. Effects of diabetes mellitus on cholesterol metabolism in man. N Engl J Med 1977; 296: 1365-71.
37. Andersen E, Karlaganis G, Sjovall J. Altered bile acid profiles in duodenal bile and urine in diabetic subjects. Eur J Clin Invest 1988; 18: 166-72.
38. Hassan AS, Ravi Subbiah MT, Thiebert P. Specific changes of bile acid metabolism in spontaneously diabetic Wistar rats. Proc Soc Exp Biol Med 1980; 164: 449-52.
39. Villanueva GR, Herreros M, Perez-Barriocanal F, Bolanos JP, Bravo P, Marin JJ. Enhancement of bile acid-induced biliary lipid secretion by streptozotocin in rats: role of insulin deficiency. J Lab Clin Med 1990; 115: 441-8.
40. Twisk J, Hoekman MF, Lehmann EM, Meijer P, Mager WH, Princen HM. Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase gene transcription. Hepatology 1995; 21: 501-10.
41. Wang DP, Stroup D, Marrapodi M, Crestani M, Galli G, Chiang JY. Transcriptional regulation of the human cholesterol 7 alpha-hydroxylase gene (CYP7A) in HepG2 cells. J Lipid Res 1996; 37: 1831-41.
42. Crestani M, Sadeghpour A, Stroup D, Galli G, Chiang JY. Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (CYP7A) by nuclear hormone receptors. J Lipid Res 1998; 39: 2192-200.
43. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J 2006; 25: 1419-25.
44. Gupta S, Stravitz RT, Dent P, Hylemon PB. Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J Biol Chem 2001; 276: 15816-22.
45. Qiao L, Han SI, Fang Y, Park JS, Gupta S, Gilfor D, et al. Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Mol Cell Biol 2003; 23: 3052-66.
46. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298: 714-9.
47. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278: 9435-40.
48. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 1365-8.
49. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999; 3: 543-53.
50. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-5.
51. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002; 296: 1703-6.
52. Urizar NL, Moore DD. GUGULIPID: a natural cholesterol-lowering agent. Annu Rev Nutr 2003; 23: 303-13.
53. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007; 67: 1383-92.
54. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000; 6: 517-26.
55. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000; 6: 507-15.
56. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003; 88: 2438-44.
57. Gwinup G, Poucher R. A controlled study of thyroid analogs in the therapy of obesity. Am J Med Sci 1967; 254: 416-20.
58. Monzani F, Caraccio N, Dardano A, Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 2004; 3: 199-210.
59. Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006; 312: 233-6.
60. Kullak-Ublick GA, Meier PJ. Mechanisms of cholestasis. Clin Liver Dis 2000; 4: 357-85.
61. Nabeshima Y. Klotho: a fundamental regulator of aging. Ageing Res Rev 2002; 1: 627-38.
62. Gilardi F, Mitro N, Godio C, Scotti E, Caruso D, Crestani M, et al. The pharmacological exploitation of cholesterol 7alpha-hydroxylase, the key enzyme in bile acid synthesis: from binding resins to chromatin remodelling to reduce plasma cholesterol. Pharmacol Ther 2007; 116: 449-72.
63. Ito S, Fujimori T, Furuya A, Satoh J, Nabeshima Y, Nabeshima Y. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J Clin Invest 2005; 115: 2202-8.
64. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-25.
65. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27: 3417-28.
66. Report of the National CHolesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood CHolesterol in Adults. The Expert Panel. Arch Intern Med 1988; 148: 36-69.
67. Bays H and Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003; 4: 779-90.
68. Gylling H, Miettinen TA. Drug-induced effects on cholesterol catabolism and bile acids. Curr Opin Investig Drugs 2006; 7: 214-8.
69. Jacobson TA, Armani A, McKenney JM and Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007; 99: 47C-55C.
70. Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, et al. Comparison of once-daily, niacin extended-release/ lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor vs Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003; 91: 667-72.
71. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084-91.
72. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004; 26: 1758-73.
73. Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106: 1024-8.
74. Dorr AE, Gundersen K, Schneider JC, Jr., Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and mortality. J Chronic Dis 1978; 31: 5-14.
75. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
76. Levy RI, Brensike JF, Epstein SE, Kelsey SF, Passamani ER, Richardson JM, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation 1984; 69: 325-37.
77. WelChol (colesevelam hydrochloride) prescribing information Daiichi Sankyo Inc, Parsippany (NJ) Available at www.welchol. com [accessed on February 19, 2008].
78. Rosenson RS, Colesevelam. HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 2006; 185: 327-30.
79. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002; 106: 1930-7.
80. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002; 22: 1175-80.
81. Kajiyama G, Tazuma S, Yamashita G, Ochi H, Miura H. Effect of MCI-196 on biliary lipids metabolism in patients with hypercholesterolemia. Rinsho Iyaku 1996; 12: 1641-92.
82. Takeuchi A, Sano N, Takikawa H. Inhibition of ileal bile acid absorption by colestimide. J Gastroenterol Hepatol 2003; 18: 548-53.
83. Matsuzaki Y. Colestimide: the efficacy of a novel anion-exchange resin in cholestatic disorders. J Gastroenterol Hepatol 2002; 17: 1133-5.
84. Homma Y, Kobayashi T, Yamaguchi H, Ozawa H, Sakane H, Nakamura H. Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia. Atherosclerosis 1997; 129: 241-8.
85. Kawashiri MA, Higashikata T, Nohara A, Kobayashi J, Inazu A, Koizumi J, et al. Efficacy of colestimide coadministered with atorvastatin in japanese patients with heterozygous familial hypercholesterolemia (FH). Circ J 2005; 69: 515-20.
86. Suzuki T, Oba K, Futami-Suda S, Suzuki K, Ouchi M, Igari Y, et al. Effects of colestimide on blood glucose-lowering activity and body weight in patients with type 2 diabetes and hypercholesterolemia. J Nippon Med Sch 2007; 74: 81-4.
87. Tasaki H, Miyamoto M, Kubara T, Kamezaki F, Tanaka S, Yamashita K, et al. Cross-over trial of intensive monotherapy with atorvastatin and combined therapy with atorvastatin and colestimide for Japanese familial hypercholesterolemia. Circ J 2006; 70: 14-20.
88. Suzuki T, Oba K, Futami S, Suzuki K, Ouchi M, Igari Y, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006; 73: 277-84.
89. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994; 121: 416-22.
90. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007; 29: 74-83.
91. Angelin B, Einarsson K, Hellstrom K, Leijd B. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. J Lipid Res 1978; 19: 1017-24.
92. Crouse JR, 3rd. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 1987; 83: 243-8.
93. Donovan JM, Von Bergmann K, Setchell KD, Isaacsohn J, Pappu AS, Illingworth DR, et al. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci 2005; 50: 1232-8.
94. a) Yamaoka-Tojo M, Tojo T, Kosugi R, Aoyama N, Niwano S, Kurokawa S, Izumi T. Effect of colestimide on reduction of body weight and waist circumference in metabolic syndrome patients with cardiovascular risk factors. Vasc Dis Prev 2008; 5: 183-189.
95. b) Bateson MC, Maclean D, Evans JR, Bouchier IA. Chenodeoxycholic acid therapy for hypertriglyceridaemia in men. Br J Clin Pharmacol 1978; 5: 249-54.
96. Grundy SM, Ahrens EH, Jr. and Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971; 78: 94-121.
97. Nestel PJ, Grundy SM. Changes in plasma triglyceride metabolism during withdrawal of bile. Metabolism 1976; 25: 1259-68.
98. Miller NE, Nestel PJ. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet 1974; 2: 929-31.
99. Garbutt JT, Kenney TJ. Effect of cholestyramine on bile acid metabolism in normal man. J Clin Invest 1972; 51: 2781-9.
100. Suzuki T, Oba K, Igari Y, Matsumura N, Watanabe K, Futami-Suda S, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 2007; 74: 338-43.
101. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386: 407-10.
102. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003; 17: 259-72.
103. Stulnig TM, Oppermann U, Steffensen KR, Schuster GU, Gustafsson JA. Liver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes 2002; 51: 2426-33.
104. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 2003; 100: 5419-24.
105. Onishi T, Sano N, Takikawa H. Effect of colestimide on absorption of unconjugated bile acids in the rat jejunum. J Gastroenterol Hepatol 2002; 17: 697-701.
106. De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 2003; 278: 39124-32.
107. Inoue Y, Yu AM, Yim SH, Ma X, Krausz KW, Inoue J, et al. Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. J Lipid Res 2006; 47: 215-27.
108. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-18.
109. Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol 2001; 21: 2991-3000.
110. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000; 14: 2831-8.
111. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14: 2819-30.
112. Ou J, Tu H, Shan B, Luk A, DeBose-Boyd RA, Bashmakov Y, et al. Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci USA 2001; 98: 6027-32.
113. Gregor MG, Hotamisligil GS. Adipocyte stress: The endoplasmic reticulum and metabolic disease. J Lipid Res 2007; 9: 1905-14.
114. Koike K, Murakami K, Nozaki N, Sugiura K, Inoue M. Colestilan, a new bile acid-sequestering resin, reduces bodyweight in postmenopausal women who have dieted unsuccessfully. Drugs R D 2005; 6: 273-9.
115. Suzuki H, Kudo H, Ishikawa Y, Nakayama T, Suzuki S, Sakamoto S. Effects of colestimide plus Bofu-tsusho-san on plasma lipids and fatty liver in perimenopausal patients. Med Postgrad 2006; 44: 35-40.
116. Wang L, Liu J, Saha P, Huang J, Chan L, Spiegelman B, et al. The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes. Cell Metab 2005; 2: 227-38.
117. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ and Edwards PA. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 2004; 18: 157-69.
118. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-5.
119. Gotto AM, Jr. Role of C-reactive protein in coronary risk reduction: focus on primary prevention. Am J Cardiol 2007; 99: 718-25.
120. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790-3.
121. Rizos E, Kostoula A, Elisaf M, Mikhailidis DP. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology 2002; 53: 273-7.
122. Tsimihodimos V, Kostoula A, Kakafika A, Bairaktari E, Tselepis AD, Mikhailidis DP, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004; 9: 27-33.
123. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and highsensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006; 97: 1198-205.
124. Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006; 10: 851-66.
125. Devaraj S, Autret B Jialal I. Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol 2006; 98: 641-3.
126. Lack L, Suliman HB, Rahman AA, Abou-Donia MB. Cholestyramine feeding lowers number of colonic apoptotic cells in rat. J Toxicol Environ Health A 2005; 68: 1963-75.
127. Date T, Shigematsu T, Kawashita Y, Satake N, Morita K. Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol Dial Transplant 2003; 18 Suppl 3: iii90-3.
128. Nitta K, Akiba T, Nihei H. Colestimide co-administered with atorvastatin attenuates the progression of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 2156.
129. Sakurai K, Fukata H, Todaka E, Saito Y, Bujo H, Mori C. Colestimide reduces blood polychlorinated biphenyl (PCB) levels. Intern Med 2006; 45: 327-8.
130. Sakurai K, Todaka E, Saito Y, Mori C. Pilot study to reduce dioxins in the human body. Intern Med 2004; 43: 792-5.
131. Safe SH. Comparative toxicology and mechanism of action of polychlorinated dibenzo-p-dioxins and dibenzofurans. Annu Rev Pharmacol Toxicol 1986; 26: 371-99.
132. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89: 495-501.
133. Asami T, Uchiyama M. Treatment of children with familial hypercholesterolemia with colestilan, a newly developed bile acid-binding resin. Atherosclerosis 2002; 164: 381-2.
134. Ast M, Frishman WH. Bile acid sequestrants. J Clin Pharmacol 1990; 30: 99-106.
135. Gallo DG, Bailey KR and Sheffner AL. The interaction between cholestyramine and drugs. Proc Soc Exp Biol Med 1965; 120: 60-5.
136. Kivisto KT, Neuvonen PJ. The effect of cholestyramine and activated charcoal on glipizide absorption. Br J Clin Pharmacol 1990; 30: 733-6.
137. Malloy MJ, Ravis WR, Pennell AT, Diskin CJ. Effect of cholestyramine resin on single dose valproate pharmacokinetics. Int J Clin Pharmacol Ther 1996; 34: 208-11.
138. Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000; 14: 681-90.
139. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-31.
140. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279: 1458-62.